DECADRON ELIXIR 500MCG/5ML ORAL LIQUID

Land: Cyprus

Taal: Grieks

Bron: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

Werkstoffen:

DEXAMETHASONE

Beschikbaar vanaf:

M S JACOVIDES & CO LTD (0000003082) 8 AYIOS NICOLAOS STR, LEFKOSIA, 1511, 21593

ATC-code:

H02AB02

INN (Algemene Internationale Benaming):

DEXAMETHASONE

Dosering:

500MCG/5ML

farmaceutische vorm:

ORAL LIQUID

Samenstelling:

DEXAMETHASONE (0000050022) 500MCG

Toedieningsweg:

ORAL USE

Prescription-type:

Εθνική Διαδικασία

Therapeutisch gebied:

DEXAMETHASONE

Product samenvatting:

Νομικό καθεστώς: Με Ιατρική Συνταγή; 1 BOTTLE X 100ML (710074001) 100 MILLILITRE - Εγκεκριμένο - Με Ιατρική Συνταγή

Productkenmerken

DECADRON 0.5MG/ML ALGORITHM SAL-LEBANON
ELIXIR
SUMMARY OF PRODUCT CHARACTERISTICS
1.
TRADE NAME OF THE MEDICINAL PRODUCT
DECADRON
®
0.5mg per 5ml Elixir 100ml
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
500mcg / 5ml
For excipients, see 6.1.
3.
PHARMACEUTICAL FORM
Liquid for oral use
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
Decadron is indicated as a treatment for certain endocrine and
non-endocrine disorders, in
certain cases of cerebral oedema, and for diagnostic testing of
adrenocortical
hyperfunction.
ENDOCRINE DISORDERS: Primary or secondary adrenocortical
insufficiency, congenital
adrenal hyperplasia.
NON
ENDOCRINE DISORDERS: Dexamethasone may be used in the treatment of non
endocrine corticosteroid responsive conditions, including:
-
Allergy and anaphylaxis: Angioneurotic oedema, anaphylaxis.
-
Arteritis collagenosis: Polymyalgia rheumatica, polyarteritis nodosa.
-
Blood disorders: Haemolytic anaemia, leukaemia, and myeloma.
-
Cardiovascular disorders: Post
myocardial infarction syndrome.
-
Gastro
intestinal: Crohn's disease, ulcerative colitis.
-
Hypercalcaemia: Sarcoidosis.
-
Infections (with appropriate chemotherapy): Miliary tuberculosis.
-
Muscular disorders: Polymyositis.
-
Neurological disorders: Raised intra-cranial pressure secondary to
cerebral
tumours.
-
Ocular disorders: Anterior and posterior uveitis, optic neuritis.
-
Renal disorders: Lupus nephritis.
-
Respiratory disease: Bronchial asthma, aspiration pneumonitis.
-
Rheumatic disorders: Rheumatoid arthritis.
-
Skin disorders: Pemphigus vulgaris.
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
GENERAL RECOMMENDATIONS FOR ORAL ADMINISTRATION
Dosage requirements are variable and must be individualized according
to the severity of
the disease and the response of the patient. The usual initial dosage
varies from 0.5 mg
to 9 mg a day depending on the disease being treated (for infants and
children, the
recommended doses usually will have to be reduced, but dosage should
be dictated by the
severity of the condition rather than by age or body